![Sarv BioLabs Paclitaxel](https://www.pharmacompass.com/image/flap/sarv-biolabs-paclitaxel-desktop-headergif-9989.gif)
![Sarv BioLabs Paclitaxel](https://www.pharmacompass.com/image/flap/sarv-biolabs-paclitaxel-mobgif-55498.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
91
PharmaCompass offers a list of Paclitaxel API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Paclitaxel manufacturer or Paclitaxel supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Paclitaxel manufacturer or Paclitaxel supplier.
PharmaCompass also assists you with knowing the Paclitaxel API Price utilized in the formulation of products. Paclitaxel API Price is not always fixed or binding as the Paclitaxel Price is obtained through a variety of data sources. The Paclitaxel Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Nab-paclitaxel manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nab-paclitaxel, including repackagers and relabelers. The FDA regulates Nab-paclitaxel manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nab-paclitaxel API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nab-paclitaxel manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nab-paclitaxel supplier is an individual or a company that provides Nab-paclitaxel active pharmaceutical ingredient (API) or Nab-paclitaxel finished formulations upon request. The Nab-paclitaxel suppliers may include Nab-paclitaxel API manufacturers, exporters, distributors and traders.
click here to find a list of Nab-paclitaxel suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nab-paclitaxel DMF (Drug Master File) is a document detailing the whole manufacturing process of Nab-paclitaxel active pharmaceutical ingredient (API) in detail. Different forms of Nab-paclitaxel DMFs exist exist since differing nations have different regulations, such as Nab-paclitaxel USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nab-paclitaxel DMF submitted to regulatory agencies in the US is known as a USDMF. Nab-paclitaxel USDMF includes data on Nab-paclitaxel's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nab-paclitaxel USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nab-paclitaxel suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Nab-paclitaxel Drug Master File in Japan (Nab-paclitaxel JDMF) empowers Nab-paclitaxel API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Nab-paclitaxel JDMF during the approval evaluation for pharmaceutical products. At the time of Nab-paclitaxel JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Nab-paclitaxel suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Nab-paclitaxel Drug Master File in Korea (Nab-paclitaxel KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Nab-paclitaxel. The MFDS reviews the Nab-paclitaxel KDMF as part of the drug registration process and uses the information provided in the Nab-paclitaxel KDMF to evaluate the safety and efficacy of the drug.
After submitting a Nab-paclitaxel KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Nab-paclitaxel API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Nab-paclitaxel suppliers with KDMF on PharmaCompass.
A Nab-paclitaxel CEP of the European Pharmacopoeia monograph is often referred to as a Nab-paclitaxel Certificate of Suitability (COS). The purpose of a Nab-paclitaxel CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Nab-paclitaxel EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Nab-paclitaxel to their clients by showing that a Nab-paclitaxel CEP has been issued for it. The manufacturer submits a Nab-paclitaxel CEP (COS) as part of the market authorization procedure, and it takes on the role of a Nab-paclitaxel CEP holder for the record. Additionally, the data presented in the Nab-paclitaxel CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Nab-paclitaxel DMF.
A Nab-paclitaxel CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Nab-paclitaxel CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Nab-paclitaxel suppliers with CEP (COS) on PharmaCompass.
A Nab-paclitaxel written confirmation (Nab-paclitaxel WC) is an official document issued by a regulatory agency to a Nab-paclitaxel manufacturer, verifying that the manufacturing facility of a Nab-paclitaxel active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nab-paclitaxel APIs or Nab-paclitaxel finished pharmaceutical products to another nation, regulatory agencies frequently require a Nab-paclitaxel WC (written confirmation) as part of the regulatory process.
click here to find a list of Nab-paclitaxel suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nab-paclitaxel as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nab-paclitaxel API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nab-paclitaxel as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nab-paclitaxel and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nab-paclitaxel NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nab-paclitaxel suppliers with NDC on PharmaCompass.
Nab-paclitaxel Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nab-paclitaxel GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nab-paclitaxel GMP manufacturer or Nab-paclitaxel GMP API supplier for your needs.
A Nab-paclitaxel CoA (Certificate of Analysis) is a formal document that attests to Nab-paclitaxel's compliance with Nab-paclitaxel specifications and serves as a tool for batch-level quality control.
Nab-paclitaxel CoA mostly includes findings from lab analyses of a specific batch. For each Nab-paclitaxel CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nab-paclitaxel may be tested according to a variety of international standards, such as European Pharmacopoeia (Nab-paclitaxel EP), Nab-paclitaxel JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nab-paclitaxel USP).